The growing interest in gene therapies was further confirmed by US Biotech major Biogen (Nasdaq: BIIB), which has reached an agreement to acquire a UK-based clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, at a price of $25.50 per share in cash.
The offer values Nightstar Therapeutics (Nasdaq: NITE), a company formed six years ago by Syncona, at $877 million, which represents a 4.5x multiple on Syncona's original investment of £56.4 million and an internal rate of return (IRR) of 72%. The sale of Nightstar will generate £254.6 million of proceeds for Syncona.
Nightstar’s US traded shares soared 66.42% to $25.23 in pre-market trading today.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze